Recruitment of renal tubular epithelial cells expressing verotoxin-1 (Stx1) receptors in HIV-1 transgenic mice with renal disease

Kidney International

Volumn 55, Issue 2, 1999, Pages 554-561

  Liu, Xue Hui ^a,b   Lingwood, Clifford A ^a,b   Ray, Patricio E ^a,b  

^a CHILDREN S RESEARCH INSTITUTE   (United States)

^b GEORGE WASHINGTON UNIVERSITY   (United States)

Author keywords

Cytotoxin; Epithelial cells; Hemolytic uremic syndrome; HIV nephropathy; Shiga like toxin receptors

Indexed keywords

RECEPTOR; VEROTOXIN;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GENE EXPRESSION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOHISTOCHEMISTRY; KIDNEY DISEASE; KIDNEY TUBULE CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; RECEPTOR BINDING; THIN LAYER CHROMATOGRAPHY; TRANSGENIC MOUSE;

EID: 0032911088     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1755.1999.00278.x     Document Type: Article

References (65)

1. 1. RAO TK, FILIPPONE EJ, NICASTRI AD, LANDESMAN SH, FRANK S, CHEN CK, FRIEDMAN EA: Associated focal and segmental glomerulosclerosis in the acquired immunodeficiency syndrome. N Engl J Med 310:669-673, 1984
2. 2. PARDO V, ALDANA M, COLTON RM, FISCHI MA, JAFFE D, MOSKOWITZ L, HENSLEY T, BOURGOIGNIE JJ: Glomerular lesions in the acquired immunodeficiency syndrome. Ann Intern Med 101:429-434, 1984
3. 3. STRAUSS J, ABITOL C, ZILLERUELO G, SCOTT G, PAREDES A, MALAGA S, MONTANE B, MITCHELL C, PARKS W, PARDO V: Renal disease in children with acquired immunodeficiency syndrome in children. N Engl J Med 321:625-630, 1991
4. 4. THOMPSON CE, DOMON LE, RIES CA, LINKER CA: Thrombotic microangiopathy in the 1980's: Clinical features, response to treatment and the impact of the immune immunodeficiency virus epidemic. Blood 80:1890-1895, 1992
5. 5. MEISENBERG BR, ROBINSON WL, MOSLEY CA, DUKE MS, RABETOY GM, KOSTY MF: Thrombotic thrombocytopenic purpura in human immunodeficiency (HIV)-seropositive males. Am J Hematol 27:212-215, 1988
6. 6. UCAR A, FERNANDEZ HF, BYRNES JJ, LIAN ECY, HARRINGTON WJ JR: Thrombotic microangiopathy and retroviral infections: A 13-year experience. Am J Hematol 54:304-309, 1994
7. 7. TURNER ME, KHER K, RAKUSSAN T, D'ANGELO L, KAPUR S, SELBY D, RAY PE: Atypical hemolytic uremic syndrome in human immunodeficiency virus-1 infected children. Pediatr Nephrol 11:161-163, 1997
8. 8. GIANANTONIO CA, VITACCO M, MENDILAHARZU F, RUTTY A, MENDILAHARZU J: The hemolytic uremic syndrome. J Pediatr 64:478-491, 1964
9. 9. FRISHBERG Y, OBRIG TG, KAPLAN BS: Hemolytic Uremic Syndrome, in Pediatric Nephrology (3rd ed), edited by HOLLIDAY MA, BARRAT TM, AVNER E, Baltimore, Williams & Wilkins, 1995, pp 871-889
10. 10. KAPLAN BS: Another step forward in our understanding of the hemolytic uremic syndrome: Tying up some loose ends. Pediatr Nephrol 9:30-32, 1995
11. 11. KARMALI MA, PETRIC M, LIM C, FLEMING PC, ARBU GS, LIOR H: The association between idiopathic hemolytic-uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 151:619-620, 1983
12. 12. KARMALI MA, STEELE BT, PETRIC M, LIM C: Sporadic cases of HUS associated with fecal cytotoxin and cytotoxin producing E. Coli in stools. Lancet 1:619-620, 1983
13. 13. NYHOLM PG, MAGNUSSON G, ZHENG Z, NOREL R, BINNINGTON-BOYD B, LINGWOOD CA: Two distinct binding sites for globotriaosyl ceramide on verotoxins: Molecular modeling and confirmation by analogues studies and a new glycolipid receptor for all verotoxins. Chem Biol 3:263-275, 1996
14. 14. O'BRIAN AD, HOLMES RK: Shiga and Shiga-like toxins. Microbiol Rev 51:206-220, 1987
15. 15. BOYD B, LINGWOOD CA: Verotoxin glycolipid receptors in renal tissues. Nephron 51:207-210, 1989
16. 16. LINGWOOD CA: Verotoxin-binding in human renal sections. Nephron 66:21-28, 1994
17. 17. ROBINSON LA, HURLEY RM, LINGWOOD CA, MATSELL DG: Escherichia coli verotoxin binding in human pediatric glomerular mesangial cells. Pediatr Nephrol 9:700-704, 1995
18. 18. TAKEDA T, DOHI S, IGARASHI T, YAMANAKA T, YOSHIYA K, KOBAYASHI N: Impairment by Verotoxin of tubular function contributes to the renal damage seen in haemolytic uraemic syndrome. J Infect Dis 27:339-341, 1993
19. 19. OBRIG TG, DEL VECCHIO PJ, BROWN JE, MORGAN TP, ROWLAND BM, JUDGE TK, ROTHMAN SW: Direct cytotoxic action of Shiga toxin on human vascular endothelial cells. Infect Immunol 56:2372-2378, 1988
20. 20. LOUISE CB, OBRIG TG: Shiga toxin-associated hemolytic uremic syndrome combined cytotoxic effects of Shiga toxin, IL-1-beta and TNF-alpha on human endothelial cells in vitro. Infect Immunol 59:4173-4179, 1991
21. 21. WADDELL T, COHEN A, LINGWOOD CA: Induction of verotoxin sensitivity in receptor-deficient cell lines using the receptor glycolipid globotriosylceramide. Proc Natl Acad Sci USA 87:7898-7901, 1990
22. 22. MORIGI M, MICHELETTI G, FIGLIUZZI M, IMBERTI B, KARMALI MA, REMUZZI A, REMUZZI G, ZOJA C: Verotoxin-1 promotes leukocyte adhesion to cultured endothelial cells under physiologic flow conditions. Blood 86:4553-4558, 1995
23. 23. OBRIG TG, LOUISE CB, LINGWOOD CA, BOYD B, BARLEY-MALONES L, DANIEL TO: Endothelial heterogeneity in Shiga toxin receptors and responses. J Biol Chem 268:15484-15488, 1993
24. 24. TESH VL, RAMEGOWDA B, SAMUEL JE: Purified Shiga-like toxins induce expression of proinflammatory cytokines from murine peritoneal macrophages. Infect Immunol 62:5085-5094, 1994
25. 25. VAN DE KAR NCAJ, MONNENS LAH, KARMALI MA, VAN HINSBERGH VW: TNF and IL-1 induce expression of the verocytotoxin receptor globtriaosylceramide on human endothelial cells: Implications for the pathogenesis of HUS. Blood 80:2755-2764, 1992
26. 26. VAN SETTEN PA, VAN HINSBERGH VWM, VAN DER VELDEN TJAN, VAN DE KAR NCAJ, VERMEER M, MAHAN JD, ASSMANN KJM, VAN DEN HEUVEL LPWJ, MONNENS LAH: Effects of TNFa on verocytoxicity in purified human glomerular microvascular endothelial cells. Kidney Int 51:1245-1256, 1997
27. 27. LEDWON PE, INGLOT AD, KNYSZ B, SIMON K, INGLOT M, GLADYSZ A: Interferon and tumor necrosis factor responses of HIV+ patients as markers for monitoring of the AIDS progression. Arch Immunol Ther Exp 42:439-445, 1994
28. 28. CHOLLET-MARTIN S, SIMON F, MATHERON S, JOSHEP CA, ELBIM C, GOUGEROT-POCIDALO MA: Comparison of plasma cytokines levels in African patients with HIV-1 and HIV-2 infection. AIDS 8:879-884, 1994
29. 29. VALDEZ H, LEDERMAN MN: Cytokines and cytokine therapies in HIV infection. AIDS Clin Rev 98:187-228, 1997
30. 30. DICKIE P, FELSER J, ECKAUS M, BRYANT JL, SILVER J, MARINOS N, NOTKINS AL: HIV-associated nephropathy in transgenic mice expressing HIV-genes. Virology 185:109-119, 1991
31. 31. KOPP JB, KLOTMAN ME, ADLER SH, BRUGGEMAN LA, ECKAUS M, DICKIE P, MARINOS NJ, BRYANT JL, NOTKINS AL, KLOTMAN PE: Progressive glomerulosclerosis and enhanced renal accumulation of basement membrane components in mice transgenic for human immunodeficiency virus type 1 genes. Proc Natl Acad Sci USA 89:1577-1581, 1992
32. 32. RAY PE, BRUGGEMAN LA, WEEKS BS, KOOP JB, BRYANT JL, OWENS JW, NOTKINS AL, KLOTMAN PE: bFGF and its low affinity receptors in the pathogenesis of HIV-associated nephropathy in transgenic mice. Kidney Int 46:759-772, 1994
33. 33. BRUGGEMAN LA, DIKMAN S, MENG C, QUAGGIN SE, COFFMAN TM, KLOTMAN PE: Nephropathy in human immunodeficiency virus-1 transgenic mice is due to renal transgene expression. J Clin Invest 100:84-92, 1997
34. 34. NUDELMAN E, KANNAGI R, HAKOMORI S, PARSONS M, LIPINSKI M, WIELS J, FELLOWS M,TURSZ TA: Glycolipid antigen associated with Burkitt lymphoma defined by a monoclonal antibody. (abstract) Science 220:509, 1983
35. 35. HALTHÖFER H, KUMPULAINEN T, RAPOLA J: Polycystic disease of the kidney: Evaluation and classification based on nephron segment and cell type specific markers. Lab Invest 62:363-369, 1990
36. 36. WILSON PD: Monolayer of microdissected renal tubule epithelial segments. J Tissue Cult Methods 13:137-141, 1991
37. 37. RAY PE, LIU HX, HENRY D, DYE L, XU L, ORENSTEIN JM, SCHUZTBANK T: Infection of human renal tubular epithelial cells with HIV-1 from children with HIV-1 associated renal disease. Kidney Int 53:1217-1229, 1998
38. 38. COHEN A, HANNIGAN GE, WILLIAMS BRG, LINGWOOD CA: Roles of globotriaosyl- and galabiosylceramide in verotoxin binding and high affinity interferon receptor. J Biol Chem 35:17088-17099, 1987
39. 39. BOYCE TG, SWEDLOW DL, GRIFFIN PM: Escherichia coli 0157:H7 and the Hemolytic Uremic Syndrome. N Engl J Med 10:364-367, 1995
40. 40. LINDGREN SW, MELTON AR, O'BRIAN AD: Virulence of entero-hemorrhagic coli 091: H21: Clinical issues in an orally infected mouse model. Infect Immunol 9:3832-3842, 1993
41. 41. LINGWOOD CA, YIU SCK: Glycolipid modification of α-interferon binding: Sequence similarity between α-interferon receptor and the verotoxin (Shiga-like toxin) B-subunit. Biochem J 283:25-26, 1992
42. 42. GHISLAIN J, LINGWOOD CA, FISH EN: Evidence for glycosphingolipid modification of the type 1 IFN receptor. J Immunol 153:3655-3663, 1994
43. 43. LINGWOOD CA: Role of verotoxin receptors in pathogenesis. Trends Microbiol 4:147-153, 1996
44. 44. SANDVIG K, VAN DEURS B: Endocytosis, intracellular transport, and cytotroxic action of Shiga toxin and ricin. Physiol Rev 76:949-966, 1996
45. 45. KHINE AA, LINGWOOD CA: Capping and receptor mediated endocytosis of cell bound verotoxin (Shiga-like toxin 1): Chemical identification of an amino acid in the B subunit necessary for efficient receptor glycolipid binding and cellular internalization. J Cell Physiol 161:319-332, 1994
46. 46. KHINE AA, LINGWOOD CA: CD77 dependent retrograde transport of CD19 to the nuclear membrane: Functional relationship between CD77 and CD19 during germinal center B-cell apoptosis. J Cell Physiol 176:281-292, 1998
47. 47. CAPOBIANCHI MR, AMEGLIO F, FEI PC, CASTILLETTI C, MERCURI F, FAIS S, DIANZANI F: Coordinate induction of interferon alpha and gamma by recombinant HIV-1 glycoprotein. AIDS Res Hum Retroviruses 9:957-962, 1993
48. 48. CAPOBIANCHI MR, ANKEL H, AMEGLIO F, PAGANELLI R, PIZZOLI PM, DIANZANI F: Recombinant glycoprotein 120 of human immunodeficiency virus is a potent interferon inducer. AIDS Res Hum Retroviruses 8:575-579, 1992
49. 49. ANKEL H, CAPOBIANCHI MR, FREZZA F, CASTILLETI C, DIANZANI F: Interferon induction by HIV-1-infected cells: A possible role of sulfatides or related glycolipids. Virology 221:113-119, 1996
50. 50. KOPP JB, MC CUNE BK, NOTKINS AL, SPORN MB, KLOTMAN PE, KOPP JB: Increased expression of transforming growth factor beta in HIV-transgenic mouse kidney. (abstract) J Am Soc Nephrol 3:600, 1992
51. 51. PUDYMAITIS A, LINGWOOD CA: Susceptibility to verotoxin as a function of the cell cycle. J Cell Physiol 50:632-639, 1992
52. 52. GRÖNE H-J, WEBER K, GRÖNE E, HELMCHEN U, OSBORN M: Coexpression of keratin and vimentin in damaged regenerating tubular epithelial of the kidney. Am J Pathol 129:1-8, 1987
53. 53. WENK J, ANDREWS PW, CASPER J, HATA J, PERA MF, VON KEITZ A, DAMJANOV I, FENDERSON BA: Glycolipids of germ cell tumors: Extended globo-series glycolipids are a hallmark of human embryonal carcinoma cells. Int J Cancer 58:108-115, 1994
54. 54. OHYAMA C, FUKUSHI Y, SATOH M, SAITOH S, ORIKASA S, NUDELMAN E, STRAUD M, HAKOMORI S: Changes in glycolipid expression in human testicular tumor. Int J Cancer 45:1040-1044, 1990
55. 55. ARAB S, RUSSEL E, CHAPMAN W, ROSEN B, LINGWOOD C: Expression of the verotoxin receptor glycolipid, globotriaosyl ceramide in Ovarian hyperplasias. Oncol Res 9:553-563, 1998
56. 56. FARKAS-HIMSLEY H, HILL R, ROSEN B, ARAB S, LINGWOOD CA: The bacterial colicin active against tumor cells in vitro and in vivo is verotoxin 1. Proc Natl Acad Sci USA 92:6996-7000, 1995
57. 57. CHATTERJEE S, SHI WY, WILSON P, MZUMDAR A: Role of lactosyl-ceramide and MAP kinase in the proliferation of proximal tubular cells in human polycystic kidney disease. J Lipid Res 37:1334-1344, 1996
58. 58. DESHMUKH G, RADIN NS, GATTONE VJ, SHAYMAN JA: Abnormalities of glycosphingolipid, sulfatide and ceramide in the polycystic (cpk/cpk) mouse. J Lipid Res 35:1611-1618, 1994
59. 59. PALLESEN G, ZEUTHENN J: Distribution of the Burkitt's lymphoma-associated antigen (BLA) in normal human tissue and malignant lymphoma as defined by immunohistological staining with monoclonal antibody 38.13. (abstract) J Cancer Res Clin Oncol 113:78, 1987
60. 60. GREGORY CD, TURSZ T, EDWARDS CF, TETAUD C, TALBOT M, CAILLOU B, RICKINSON AB, LIPINSKI M: Identification of a subset of normal B cells with a Burkitt's lymphoma (BL)-like phenotype. J. Immunology 139:313-318, 1987
61. 61. MALONEY MD, LINGWOOD CA: CD19 has a potential CD77 (globotriaosyl ceramide)-binding site with sequence similarity to vero-toxin B-subunits: Implications of molecular mimicry for B cell adhesion and enterohemorrhagic Escherichia coli pathogenesis. J Exp Med 180:191-201, 1994
62. 62. COHEN A, MADRID-MARINA V, ESTROV Z, FREEDMAN M, LINGWOOD CA, DOSCH H-M: Expression of glycolipid receptors to Shiga-like toxin on human B lymphocytes: A mechanism for the failure of long-lived antibody response to dysenteric disease. Int Immunol 2:1-8, 1990
63. 63. MANGENEY M, LINGWOOD CA, TAGA S, CAILLOU B, TURSZ T, WIELS J: Apoptosis induced in Burkitt's lymphoma cells via Gb3/CD77, a glycolipid antigen. Cancer Res 53:5314-5319, 1993
64. 64. MANGENEY M, RICHARD Y, COULAUD D, TURSZ T, WIELS J: CD77: An antigen of germinal center B cells entering apoptosis. Eur J Immunol 5:1131-1140, 1991
65. 65. BOYD B, TYREEL G, MALONEY M, GYLES C, BRUTON J, LINGWOOD CA: Alteration of the glycolipid binding specificity of the pig edema toxin from globotetraosyl to globotriaosyl ceramide alters in vivo tissue targeting and results in a verotoxin 1-like disease in pigs. J Exp Med 177:1745-1753, 1993